|Articles|July 10, 2018

Transmission of NDM Bacteria Between Dogs and Humans is Established

In 2015, a New Delhi-metallo-beta-lactamase (NDM) Escherichia coli bacteria was discovered in two Finnish dogs. An article recently published in the journal Eurosurveillance reveals that the dogs' owner did also carry the bacterium. This is presumably the first time in the world that the transmission of NDM-bacteria between a dog and a human has been reported.

"We were able, through the analysis of the genome of the bacteria, to conclude that the bacterial isolates from the dogs and humans were identical, which means that they were transmitted between dogs and humans," says DVM (PhD) Thomas Grönthal, the corresponding author of the study, at the Faculty of veterinary medicine, University of Helsinki.

The bacteria had been transmitted between dogs and humans

The NDM-bacteria that had originally been isolated from ear specimens from two dogs in the same family initiated an investigation about the spread and origin of the bacteria. Specimens were also taken from family members and the dogs. The relatedness of the bacteria were investigated by examining the nucleotide sequence of their genome. The study was a collaboration between the University of Helsinki, the National Institute of Health and Welfare, and the Finnish Food Safety Authority Evira.

An extremely resistant NDM-5 producing bacterial strain was isolated from the family dogs and one of the family members. In addition, both dogs and two family members carried a multidrug-resistant ESBL bacterium. The NDM and ESBL bacterial strains that were isolated from the dogs and humans were identical. The humans were asymptomatic. The origin of the NDM bacteria was not discovered in this study.

"We could not show with certainty in which direction the bacteria had transmitted. However, especially the NDM-bacteria probably moved from human to dog as these bacteria have not previously been identified in animals in Finland," assesses docent and leader of the research Merja Rantala from the University of Helsinki.

"The use of carbapenem antibiotics in animals is prohibited in Finland, but the dogs had received numerous other antibiotics. This gave the NDM-bacteria a competitive edge and enabled them to persist in the dogs," says Rantala.

Are carbapenemase-producing bacteria becoming more common in animals?

This study is presumably the first where the transfer of NDM-bacteria between dogs and humans has been demonstrated. The NDM-5 bacterium is very rare in dogs; it has only been isolated in Algeria previously. Other carbapenem-resistant bacteria have been reported in dogs in the United States, France and Germany. They are, however, being reported in animals at an increasing pace. The research group recommends that laboratories investigating animal specimens should monitor the susceptibility of bacteria to carbapenems and extended spectrum cephalosporins.

Source: University of Helsinki

Newsletter

Stay prepared and protected with the Infection Control Today newsletter, delivering essential updates, best practices, and expert insights for infection prevention professionals.

Subscribe

Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.